Home / CHF / Sandoz’ Rituximab Biosimilar Rixathon Wins EC Clearance

Sandoz’ Rituximab Biosimilar Rixathon Wins EC Clearance

Roche reported MabThera/Rituxan sales of CHF 1.9 billion (approximately $1.95 billion) in the first quarter of 2017, up 4% on Q1 2016 sales.